Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 10, 2025
Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers
Read more at globenewswire.com
